Brooks Laboratories Ltd
NSE:BROOKS
Brooks Laboratories Ltd
Common Shares Outstanding
Brooks Laboratories Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Brooks Laboratories Ltd
NSE:BROOKS
|
Common Shares Outstanding
â‚ą26.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
||
Divi's Laboratories Ltd
NSE:DIVISLAB
|
Common Shares Outstanding
â‚ą265.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
||
Suven Life Sciences Ltd
NSE:SUVEN
|
Common Shares Outstanding
â‚ą218.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
||
Dishman Carbogen Amcis Ltd
NSE:DCAL
|
Common Shares Outstanding
â‚ą156.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
||
Syngene International Ltd
NSE:SYNGENE
|
Common Shares Outstanding
â‚ą401.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
||
I
|
Innova Captab Ltd
NSE:INNOVACAP
|
Common Shares Outstanding
â‚ą57.2m
|
CAGR 3-Years
6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Brooks Laboratories Ltd
Glance View
Brooks Laboratories Ltd. is a research and development driven pharmaceutical manufacturing company. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2011-09-02. The firm operates through the Pharmaceuticals segment. The company manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup and eye/ear drops. Its products under Carbapenem category includes Imipenem 250mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 125mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, Doripenem 500mg and Doripenem 1000mg. The company offers Penicillins in the form of injections, tablets and dry syrup. Its General category of products include liquid injections, dry powder injections and eye/ear drops. The firm has two manufacturing plants, which are located at Baddi in Himachal Pradesh and Vadodara in Gujarat. The firm manufactures and markets the pharmaceuticals nationally and internationally to various regulated markets.
See Also
What is Brooks Laboratories Ltd's Common Shares Outstanding?
Common Shares Outstanding
26.2m
INR
Based on the financial report for Sep 30, 2024, Brooks Laboratories Ltd's Common Shares Outstanding amounts to 26.2m INR.
What is Brooks Laboratories Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
3%
Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for Brooks Laboratories Ltd have been 2% over the past three years , 5% over the past five years , and 3% over the past ten years .